Participant flow

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma · Source last updated 2014-12-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Gemcitabine 900 mg/m2 on days 1 and 8 intravenously over 90 minutes, followed by Docetaxel 75 mg/m2 on day 8 intravenously over 1 hour.

   id

   FG000

   title

   Women Treated With Adjuvant Regimen for High Risk Uterine LMS

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Death

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         47

      type

      STARTED

   2. achievements

      1. comment

         One patient died during cycle 1 of treatment because of infectious complications of AIDS.

         group Id

         FG000

         num Subjects

         46

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

This was multi-center study open at 11 major medical centers across the United States.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice